Déjà vu: Canada’s drug reviewers again mired in bureaucracy
16 février 2015 • Par Adam CookThe development of treatment for the cure of hepatitis C (HCV) is moving at a dizzying pace. Indeed, the entire HCV story is one of an unusually fast trajectory, not only the speed of treatment development, but also the spread of the virus. While early cures were injection-based, difficult to tolerate, and boasting a mere 50% success rate after a year of treatment, there now exist cures that involve one pill, once a day, for a regimen that often doesn’t exceed twelve weeks. There are clinical trials being conducted presently to evaluate the efficacy of new treatments at eight and...
